Similar to cutaneous melanoma, immune checkpoint inhibitors and BRAF/MEK inhibitors are used as the first-line treatment for metastatic NAM, but data on the efficacy of these therapies remain scarce. The gene discussed is MAP2K7; the disease is Bailey-Bloch congenital myopathy.